Income Statement
CORVUS PHARMACEUTICALS, INC.
CRVS
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue
|
- | - | - | - | - | - | - | - | - | - |
|
Cost of Revenue
|
- | - | - | - | - | - | - | - | - | - |
|
Gross Profit
|
- | - | - | - | - | - | - | - | - | - |
|
Operating Expenses
|
42.97 | 27.55 | 23.41 | 32.57 | 38.63 | 43.76 | 48.85 | 49.22 | 56.52 | 36.98 |
|
Research & Development
|
33.72 | 19.39 | 16.53 | 24.47 | 29.12 | 31.83 | 37.98 | 38.59 | 46.31 | 29.36 |
|
Selling, General & Administrative
|
9.25 | 8.16 | 6.88 | 8.10 | 9.52 | 11.93 | 10.88 | 10.64 | 10.22 | 7.62 |
|
Other Operating Expenses
|
- | - | - | - | - | - | - | - | - | - |
|
Operating Income
|
-42.97 | -27.55 | -23.41 | -32.57 | -38.63 | -43.76 | -48.85 | -49.22 | -56.52 | -36.98 |
|
Non-Operating Income
|
27.69 | 34.75 | - | - | - | - | - | - | - | - |
|
Interest Income
|
- | - | - | - | - | - | - | - | - | - |
|
Interest Expense
|
- | - | - | - | - | - | - | - | - | - |
|
Other Non-Op Income / Expense
|
-1.96 | -3.20 | -5.28 | -10.01 | -4.83 | -0.23 | - | - | - | - |
|
Income Before Tax
|
-13.33 | -59.10 | -27.03 | -41.31 | -43.24 | -6.00 | -46.67 | -46.94 | -55.66 | -36.38 |
|
Income Tax Expense
|
1.96 | 3.20 | - | - | - | - | - | - | - | - |
|
Non-Controlling Interest
|
- | - | - | - | - | - | - | - | - | - |
|
Net Income
|
-15.28 | -62.29 | -27.03 | -41.31 | -43.24 | -6.00 | -46.67 | -46.94 | -55.66 | -36.38 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY | Dec 31, 2024 2024 FY | Dec 31, 2023 2023 FY | Dec 31, 2022 2022 FY | Dec 31, 2021 2021 FY | Dec 31, 2020 2020 FY | Dec 31, 2019 2019 FY | Dec 31, 2018 2018 FY | Dec 31, 2017 2017 FY | Dec 31, 2016 2016 FY |
|---|---|---|---|---|---|---|---|---|---|---|
|
Depreciation & Amortization
|
- | - | - | - | - | - | - | - | - | - |
|
EBITDA
|
-42.87 | -27.46 | -23.26 | -32.20 | -38.17 | -43.13 | -48.11 | -48.38 | -55.68 | -36.98 |
|
Earnings Per Share (Basic)
|
-0.19 | -1.02 | -0.56 | -0.89 | -1.03 | - | - | - | - | - |
|
Diluted EPS
|
-0.53 | -1.02 | -0.56 | -0.89 | -1.03 | - | - | - | - | - |
|
Weighted Average Shares
|
78.96 | 60.99 | 48.03 | 46.55 | 41.85 | - | - | - | - | - |
|
Diluted Weighted Avg Shares
|
79.74 | 60.99 | 48.03 | 46.55 | 41.85 | - | - | - | - | - |
|
Comprehensive Income
|
-14.89 | -62.61 | -27.43 | -43.74 | -41.38 | -6.02 | -46.61 | -46.93 | -55.67 | -36.37 |